|
1
|
Mikula-Pietrasik J, Witucka A, Pakula M,
Uruski P, Begier-Krasińska B, Niklas A, Tykarski A and Książek K:
Comprehensive review on how platinum- and taxane-based chemotherapy
of ovarian cancer affects biology of normal cells. Cell Mol Life
Sci. 76:681–697. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kujawa KA and Lisowska KM: Ovarian
cancer-from biology to clinic. Postepy Hig Med Dosw (Online).
2:1275–1290. 2015.(In Polish). View Article : Google Scholar
|
|
4
|
Aasen T, Mesnil M, Naus CC, Lampe PD and
Laird DW: Gap junctions and cancer: Communicating for 50 years. Nat
Rev Cancer. 16:775–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruch RJ: Connexin43 suppresses lung cancer
stem cells. Cancers (Basel). 11(pii): E1752019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzhi Z, Liang T, Yuexia P, Lucy L,
Xiaoting H, Yuan Z and Qin W: Gap junctions enhance the
antiproliferative effect of MicroRNA-124-3p in glioblastoma cells.
J Cell Physiol. 230:2476–2488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Polusani SR, Kalmykov EA, Chandrasekhar A,
Zucker SN and Nicholson BJ: Cell coupling mediated by connexin 26
selectively contributes to reduced adhesivity and increased
migration. J Cell Sci. 129:4399–4410. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Q, Boire A, Jin X, Valiente M, Er EE,
Lopez-Soto A, Jacob L, Patwa R, Shah H, Xu K, et al:
Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP
transfer. Nature. 533:493–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawasaki Y, Omori Y, Li Q, Nishikawa Y,
Yoshioka T, Yoshida M, Ishikawa K and Enomoto K: Cytoplasmic
accumulation of connexin32 expands cancer stem cell population in
human HuH7 hepatoma cells by enhancing its self-renewal. Int J
Cancer. 128:51–62. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Q, Omori Y, Nishikawa Y, Yoshioka T,
Yamamoto Y and Enomoto K: Cytoplasmic accumulation of connexin32
protein enhances motility and metastatic ability of human hepatoma
cells in vitro and in vivo. Int J Cancer. 121:536–546. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu W, Fan L, Bao Z, Zhang Y, Peng Y, Shao
M, Xiang Y, Zhang X, Wang Q and Tao L: The cytoplasmic
translocation of Cx32 mediates cisplatin resistance in ovarian
cancer cells. Biochem Biophys Res Commun. 487:292–299. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Tao L, Fan LX, Huang K, Luo HM,
Ge H, Wang X and Wang Q: Cx32 mediates cisplatin resistance in
human ovarian cancer cells by affecting drug efflux transporter
expression and activating the EGFR-Akt pathway. Mol Med Rep.
19:2287–2296. 2019.PubMed/NCBI
|
|
13
|
Zhao Y, Lai Y, Ge H, Guo Y, Feng X, Song
J, Wang Q, Fan L, Peng Y, Cao M, et al: Non-junctional Cx32
mediates anti-apoptotic and pro-tumor effects via epidermal growth
factor receptor in human cervical cancer cells. Cell Death Dis.
8:e27732017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiang Y, Wang Q, Guo Y, Ge H, Fu Y, Wang X
and Tao L: Cx32 exerts anti-apoptotic and pro-tumor effects via the
epidermal growth factor receptor pathway in hepatocellular
carcinoma. J Exp Clin Cancer Res. 38:1452019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saeki Y: Ubiquitin recognition by the
proteasome. J Biochem. 161:113–124. 2017.PubMed/NCBI
|
|
16
|
Kwon YT and Ciechanover A: The ubiquitin
code in the ubiquitin-proteasome system and autophagy. Trends
Biochem Sci. 42:873–886. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salat-Canela C, Munoz MJ, Sese M, Ramon y
Cajal S and Aasen T: Post-transcriptional regulation of connexins.
Biochem Soc Trans. 43:465–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aasen T, Johnstone S, Vidal-Brime L, Lynn
KS and Koval M: Connexins: Synthesis, Post-translational
modifications, and trafficking in health and disease. Int J Mol
Sci. 19(pii): E12962018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Spagnol G, Kieken F, Kopanic JL, Li H,
Zach S, Stauch KL, Grosely R and Sorgen PL: Structural studies of
the Nedd4 WW domains and their selectivity for the Connexin43
(Cx43) Carboxyl terminus. J Biol Chem. 291:7637–7650. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Totland MZ, Bergsland CH, Fykerud TA,
Knudsen LM, Rasmussen NL, Eide PW, Yohannes Z, Sørensen V, Brech A,
Lothe RA and Leithe E: The E3 ubiquitin ligase NEDD4 induces
endocytosis and lysosomal sorting of connexin 43 to promote loss of
gap junctions. J Cell Sci. 130:2867–2882. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun J, Hu Q, Peng H, Peng C, Zhou L, Lu J
and Huang C: The ubiquitin-specific protease USP8 deubiquitinates
and stabilizes Cx43. J Biol Chem. 293:8275–8284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee BH, Lee MJ, Park S, Oh DC, Elsasser S,
Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, et al: Enhancement
of proteasome activity by a small-molecule inhibitor of USP14.
Nature. 467:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Yang Q, Chen J, Zhang P, Huang Q,
Zhang X, Yang L, Xu D, Zhao C, Wang X and Liu J: Inhibition of
proteasomal deubiquitinase by silver complex induces apoptosis in
non-small cell lung cancer cells. Cell Physiol Biochem. 49:780–797.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia X, Liao Y, Guo Z, Li Y, Jiang L, Zhang
F, Huang C, Liu Y, Wang X, Liu N, et al: Targeting
proteasome-associated deubiquitinases as a novel strategy for the
treatment of estrogen receptor-positive breast cancer. Oncogenesis.
7:752018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Wang J, Zhong J, Deng Y, Xi Q, He
S, Yang S, Jiang L, Huang M, Tang C and Liu R: Ubiquitin-specific
protease 14 (USP14) regulates cellular proliferation and apoptosis
in epithelial ovarian cancer. Med Oncol. 32:3792015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu Y, Ma G, Liu G, Li B, Li H, Hao X and
Liu L: USP14 as a novel prognostic marker promotes cisplatin
resistance via Akt/ERK signaling pathways in gastric cancer. Cancer
Med. 7:5577–5588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu X, Meng Y, Xu L, Qiu L, Wei M, Su D, Qi
X, Wang Z, Yang S, Liu C and Han J: Cul4 E3 ubiquitin ligase
regulates ovarian cancer drug resistance by targeting the
antiapoptotic protein BIRC3. Cell Death Dis. 10:1042019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu Y, Han D, Liu W, Huang R, Ou J, Chen X,
Zhang X, Wang X, Li S, Wang L, et al: RNF138 confers cisplatin
resistance in gastric cancer cells via activating Chk1 signaling
pathway. Cancer Biol Ther. 19:1128–1138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L, Liu T, Li Y, Wu C, Luo K, Yin Y,
Chen Y, Nowsheen S, Wu J, Lou Z and Yuan J: The deubiquitinase
USP9X promotes tumor cell survival and confers chemoresistance
through YAP1 stabilization. Oncogene. 37:2422–2431. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Denkert C, Budczies J, Darb-Esfahani S,
Györffy B, Sehouli J, Könsgen D, Zeillinger R, Weichert W, Noske A,
Buckendahl AC, et al: A prognostic gene expression index in ovarian
cancer-validation across different independent data sets. J Pathol.
218:273–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed AA, Mills AD, Ibrahim AE, Temple J,
Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, et
al: The extracellular matrix protein TGFBI induces microtubule
stabilization and sensitizes ovarian cancers to paclitaxel. Cancer
Cell. 12:514–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mok SC, Bonome T, Vathipadiekal V, Bell A,
Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al: A
gene signature predictive for outcome in advanced ovarian cancer
identifies a survival factor: Microfibril-associated glycoprotein
2. Cancer Cell. 16:521–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Konstantinopoulos PA, Spentzos D, Karlan
BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA and Cannistra
SA: Gene expression profile of BRCAness that correlates with
responsiveness to chemotherapy and with outcome in patients with
epithelial ovarian cancer. J Clin Oncol. 28:3555–3561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marchion DC, Cottrill HM, Xiong Y, Chen N,
Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, et
al: BAD phosphorylation determines ovarian cancer chemosensitivity
and patient survival. Clin Cancer Res. 17:6356–6366. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gentric G, Kieffer Y, Mieulet V, Goundiam
O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, et
al: PML-regulated mitochondrial metabolism enhances
chemosensitivity in human ovarian cancers. Cell Metab.
29:156–173.e110. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bonome T, Levine DA, Shih J, Randonovich
M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC,
Boyd J and Birrer MJ: A gene signature predicting for survival in
suboptimally debulked patients with ovarian cancer. Cancer Res.
68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vathipadiekal V, Wang V, Wei W, Waldron L,
Drapkin R, Gillette M, Skates S and Birrer M: Creation of a human
secretome: A novel composite library of human secreted proteins:
Validation using ovarian cancer gene expression data and a virtual
secretome array. Clin Cancer Res. 21:4960–4969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
King ER, Tung CS, Tsang YT, Zu Z, Lok GT,
Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, et al: The
anterior gradient homolog 3 (AGR3) gene is associated with
differentiation and survival in ovarian cancer. Am J Surg Pathol.
35:904–912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ferriss JS, Kim Y, Duska L, Birrer M,
Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene
expression predictors of single drug responses to adjuvant
chemotherapy in ovarian carcinoma: Predicting platinum resistance.
PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koti M, Gooding RJ, Nuin P, Haslehurst A,
Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et
al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling
networks associated with chemotherapy resistance and treatment
response in high-grade serous epithelial ovarian cancer. BMC
Cancer. 13:5492013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarząb M, Student S,
Rzepecka IK, Jarząb B and Kupryjańczyk J: Gene expression analysis
in ovarian cancer-faults and hints from DNA microarray study. Front
Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S,
Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, et al: Integrated
copy number and expression analysis identifies profiles of
whole-arm chromosomal alterations and subgroups with favorable
outcome in ovarian clear cell carcinomas. PLoS One.
10:e01280662015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao C, Chen X, Zang D, Lan X, Liao S,
Yang C, Zhang P, Wu J, Li X, Liu N, et al: Platinum-containing
compound platinum pyrithione is stronger and safer than cisplatin
in cancer therapy. Biochem Pharmacol. 116:22–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Goldberg GS, Bechberger JF and Naus CC: A
pre-loading method of evaluating gap junctional communication by
fluorescent dye transfer. Biotechniques. 3:490–497. 1995.
|
|
49
|
Koreen IV, Elsayed WA, Liu YJ and Harris
AL: Tetracycline-regulated expression enables purification and
functional analysis of recombinant connexin channels from mammalian
cells. Biochem J. 383:111–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Didier R, Mallavialle A, Ben Jouira R,
Domdom MA, Tichet M, Auberger P, Luciano F, Ohanna M,
Tartare-Deckert S and Deckert M: Targeting the
proteasome-associated deubiquitinating enzyme USP14 impairs
melanoma cell survival and overcomes resistance to MAPK-targeting
therapies. Mol Cancer Ther. 17:1416–1429. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jamieson S, Going JJ, D'Arcy R and George
WD: Expression of gap junction proteins connexin 26 and connexin 43
in normal human breast and in breast tumours. J Pathol. 184:37–43.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Govindarajan R, Zhao S, Song XH, Guo RJ,
Wheelock M, Johnson KR and Mehta PP: Impaired Trafficking of
connexins in androgen-independent human prostate cancer cell lines
and its mitigation by alpha-catenin. J Biol Chem. 277:50087–50097.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Toler CR, Taylor DD and Gercel-Taylor C:
Loss of communication in ovarian cancer. Am J Obstet Gynecol.
194:e27–e31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ribeiro-Rodrigues TM, Catarino S, Marques
C, Ferreira JV, Martins-Marques T, Pereira P and Girão H:
AMSH-mediated deubiquitination of Cx43 regulates internalization
and degradation of gap junctions. FASEB J. 28:4629–4641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Girao H, Catarino S and Pereira P: Eps15
interacts with ubiquitinated Cx43 and mediates its internalization.
Exp Cell Res. 315:3587–3597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Auth T, Schluter S, Urschel S, Kussmann P,
Sonntag S, Höher T, Kreuzberg MM, Dobrowolski R and Willecke K: The
TSG101 protein binds to connexins and is involved in connexin
degradation. Exp Cell Res. 315:1053–1062. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Alaei SR, Abrams CK, Bulinski JC,
Hertzberg EL and Freidin MM: Acetylation of C-terminal lysines
modulates protein turnover and stability of Connexin-32. BMC Cell
Biol. 19:222018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xiao D, Chen S, Shao Q, Chen J, Bijian K,
Laird DW and Alaoui-Jamali MA: Dynamin 2 interacts with connexin 26
to regulate its degradation and function in gap junction formation.
Int J Biochem Cell Biol. 55:288–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jung H, Kim BG, Han WH, Lee JH, Cho JY,
Park WS, Maurice MM, Han JK, Lee MJ, Finley D and Jho EH:
Deubiquitination of Dishevelled by Usp14 is required for Wnt
signaling. Oncogenesis. 2:e642013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Meng Q, Cai C, Sun T, Wang Q, Xie W, Wang
R and Cui J: Reversible ubiquitination shapes NLRC5 function and
modulates NF-κB activation switch. J Cell Biol. 211:1025–1040.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xu D, Shan B, Sun H, Xiao J, Zhu K, Xie X,
Li X, Liang W, Lu X, Qian L and Yuan J: USP14 regulates autophagy
by suppressing K63 ubiquitination of Beclin 1. Genes Dev.
30:1718–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sharma A, Alswillah T, Singh K, Chatterjee
P, Willard B, Venere M, Summers MK and Almasan A: USP14 regulates
DNA damage repair by targeting RNF168-dependent ubiquitination.
Autophagy. 14:1976–1990. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Walters BJ, Hallengren JJ, Theile CS,
Ploegh HL, Wilson SM and Dobrunz LE: A catalytic independent
function of the deubiquitinating enzyme USP14 regulates hippocampal
synaptic short-term plasticity and vesicle number. J Physiol.
592:571–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jarome TJ, Kwapis JL, Hallengren JJ,
Wilson SM and Helmstetter FJ: The ubiquitin-specific protease 14
(USP14) is a critical regulator of long-term memory formation.
Learn Mem. 21:9–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lee BH, Lu Y, Prado MA, Shi Y, Tian G, Sun
S, Elsasser S, Gygi SP, King RW and Finley D: USP14 deubiquitinates
proteasome-bound substrates that are ubiquitinated at multiple
sites. Nature. 532:398–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu B, Jiang S, Li M, Xiong X, Zhu M, Li
D, Zhao L, Qian L, Zhai L, Li J, et al: Proteome-wide analysis of
USP14 substrates revealed its role in hepatosteatosis via
stabilization of FASN. Nat Commun. 9:47702018. View Article : Google Scholar : PubMed/NCBI
|
